The 6 analysts offering 12-month price forecasts for CureVac NV have a median target of 19.46, with a high estimate of 50.19 and a low estimate of 14.67. The median estimate represents a +30.20% increase from the last price of 14.95.
The current consensus among 7 polled investment analysts is to Hold stock in CureVac NV. This rating has held steady since July, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.26
Reporting Date Aug 15
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.